Eptifibatide (Integrilin®) is a highly specific, reversible, intravenously administered
glycoprotein (GP) Ilb/IIIa receptor antagonist that acts at the final common step of the platelet …

Purpose. According to guidelines from the American College of Chest Physicians, low-
molecular-weight heparin (LMWH) and unfractionated heparin (UFH) should be prescribed …

Introduction: Acute coronary syndromes and non-Q-wave myocardial infarction are often
initiated by platelet activation. Eptifibatide is a cyclic heptapeptide and is the third inhibitor of …

Percutaneous coronary intervention (PCI) is one of the most common medical procedures
performed for treatment of coronary artery disease. Antiplatelet medications as adjunctive …

BACKGROUND: Patients undergoing percutaneous coronary intervention (PCI) with stent
placement are often prescribed glycoprotein IIb/IIIa inhibitors. However, drug selection is …

The previously described fusion protein BLAH 6 (Marques JA et al., Thromb Haemost 2001;
86: 902–8) is a recombinant protein that combines the small disintegrin barbourin with …

The glycoprotein (GP) IIb/IIIa receptor serves as the final common pathway of platelet-
thrombus formation. Thus, the GP IIb/IIIa receptor has been identified as a target for the …

The role of small molecules anti‐glycoprotein (GP) IIb/IIIa pharmacotherapy during acute
myocardial infarction (AMI) has not been established. The purpose of our study was to …

Abstract Objective: Three GPIIb/IIIa antagonists are available in the market. In France, as in
many countries, their acquisition costs strongly differ. The objective of this study was to …

Abstract Background Glycoprotein IIb/IIIa inhibitor use in acute ischemic stroke (AIS) during
mechanical thrombectomy (MT) and acute stenting and angioplasty is a topic consistently …